Synthesis of cryptophycin 52 using the shi epoxidation

Organic Letters

Volumn 4, Issue 10, 2002, Pages 1813-1815

  Hoard, David W ^a   Moher, Eric D ^a   Martinelli, Michael J ^a   Norman, Bryan H ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CRYPTOPHYCIN 52; DEPSIPEPTIDE; EPOXIDE; LACTAM; LACTONE; PACLITAXEL;

ARTICLE; CHEMISTRY; CYANOBACTERIUM; DRUG RESISTANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SYNTHESIS;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYANOBACTERIA; DEPSIPEPTIDES; DRUG RESISTANCE, NEOPLASM; EPOXY COMPOUNDS; LACTAMS; LACTONES; PACLITAXEL;

EID: 0037118322     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol025933+     Document Type: Article

References (26)

1. For recent reviews, see: (a) Shih, C.; Al-Awar, R. S.; Fray, A. H.; Martinelli, M. J.; Moher, E. D.; Norman, B. H.; Patel, V. F.; Shultz, R. M.; Toth, J. E.; Varie, D. L.; Corbett, T. H.; Moore, R. E. In Anticancer Agents: Frontiers in Cancer Chemotherapy; Ojima, I., Vite, G. D., Altman, K., Eds.; Washington, DC, 2001; Vol. 796, pp 171-189.
2. (b) Eggen, M.J.; Georg, G. I. Med. Res. Rev. 2002, 22, 85.
3. Schwartz, R. E.; Hirsch, C. F.; Sesin, D. F.; Flor, J. E.; Chartrain, M.; Fromtling, R. E.; Harris, G. H.; Salvatore, M. J.; Liesch, J. M.; Yudin, K. J. Ind. Microbiol. 1990, 5, 113.
4. Trimurtulu, G.; Ohtani, I.; Patterson, G. M. L.; Moore, R. E.; Corbett, T. H.; Valeriote, F. A.; Demchik, L. J. Am. Chem. Soc. 1994, 116, 4729.
5. Golakoti, T.; Ogino, J.; Heltzel, C. E.; Husebo, T. L.; Jensen, C. M.; Larsen, L. K.; Patterson, G. M. L.; Moore, R. E.; Mooberry, S. L.; Corbett, T. H.; Valeriote, F. A. J. Am. Chem. Soc. 1995, 117, 12030.
6. (a) Moore, R. E.; Tius, M. A.; Barrow, R. A.; Liang, J.; Corbett, T. H.; Valeriote, F. A.; Hemscheidt, T. K. PCT Int. Appl. WO 9640184 A1 19961219, 1996.
7. (b) Wagner, M. M.; Paul, D. C.; Shih, C.; Jordan, M. A.; Wilson, L.; Williams, D. C. Cancer Chemother. Pharmacol. 1999, 43, 115 and references therein.
8. Kobayashi, M.; Kurosu, M.; Wang, W.; Kitigawa, I. Chem. Pharm. Bull. (Japan) 1994, 42, 2394.
9. Barrow, R. A.; Hemscheidt, T.; Liang, J.; Paik, S.; Moore, R. E.; Tius, M. A. J. Am. Chem. Soc. 1995, 117, 2479.
10. For example, see: Eggen, M.; Nair, S. K.; Georg, G. I. Org. Lett. 2001, 3, 1813 and references therein.
11. Fray, A. H. Tetrahedron: Asymmetry 1998, 9, 2777.
12. Tu, Y.; Wang, Z.-X.; Shi, Y. J. Am. Chem. Soc. 1996, 118, 9806.
13. Jacobsen Asymmetric Epoxidation (JAE): Jacobsen, E. N.; Zhang, W.; Muci, A. R.; Ecker, J. R.; Deng, L. J. Am. Chem. Soc. 1991, 113, 7063.
14. Yamada, T.; Takai, T.; Rhode. O.; Mukaiyama, T. Chem. Lett. 1991, 1.
15. Adam, W.; Mitchell, C. Angew. Chem., Int. Ed. Engl. 1996, 35, 533.
16. Kluge, R.; Schulz, M.; Liebsch, S. Tetrahedron 1996, 52, 2957.
17. Kende, A. S.; Delair, P.; Blass, B. E. Tetrahedron Lett. 1994, 35, 8123.
18. 5a,7 route. It was necessary to switch from Boc to Fmoc since the bcnzylic epoxide was not compatible with the acidic conditions necessary to remove the Boc group at a later point in the synthesis.
19. Wang, Z.-X.; Yong, T.; Frohn, M.; Shi, Y. J. Org. Chem. 1997, 62, 2328.
20. 1H NMR and mass spectral data consistent with their assigned structure.
21. 5a in two steps: (a) HCl, EtOAc, 91%;
22. 3, dioxane, water, 93%.
23. Premixing of all the components with DCC addition last, which is the typical protocol for DCC-mediated esterifications, led to the production of acylated tetrahydrofuran i as a byproduct (20%) contaminating 14. (matrix presented)
24. Yield of β-epoxide, corrected for 10% α-epoxide present as a contaminant.
25. (a) Patel, V. F.; Andis, S. L.; Kennedy, J. H.; Ray, J. E.; Schultz, R. M. J. Med. Chem. 1999, 42, 2588.
26. (b) Also see ref 5a.